Halia Therapeutics Published in Journey of Drug Targeting
August 28, 2025
A Halia publication has been featured in the Journey of Drug Targeting: “Ofirnoflast (HT-6184): A first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation.” Ofirnoflast targets inflammation at its source by preventing NLRP3 inflammasome formation and promoting its disassembly – essentially disrupting the root cause rather than just managing symptoms.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
